Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Hepatitis C Virus

In brief

The purpose of this study is to evaluate the effectiveness of BMS-986094 and Daclatasvir (DCV) when given in combination with or without Ribavirin

Key facts

Study ID

NCT01629732

Run by

Bristol-Myers Squibb

People needed

0

Starts

2013-03-01

Expected to finish

2014-06-01

Last updated by the study team

2014-05-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females, ≥ 18 years of age
• Subjects chronically infected with Hepatitis C virus (HCV) genotype 1,2,3 or 4
• HCV RNA viral load ≥ 10,000 IU/mL
• Subjects with compensated cirrhosis are permitted (compensated cirrhotics are capped at approximately 25% of treated population)
• Body Mass Index (BMI) of 18 to 35 kg/m2
• Seronegative for Hepatitis C virus (HIV) and Hepatitis B

You may not qualify if…

• Evidence of decompensated liver disease
• Evidence of medical condition contributing to chronic liver disease other than HCV

Where it is running

• Local Institution — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.